We are Magle Group
The Magle Group aims to establish itself as a leader in high-quality life-changing healthcare innovations to meet medical needs through scientific excellence. The Group’s proprietary and proven technology platform of degradable starch microspheres (DSM) serving as the base for development of new products.
Driving growth and diversifying risk
The Magle Group is founded on strategic acquisitions aimed at driving growth and diversifying risk. Magle AB (formed in 1995 as a pure development company) acquired Chemoswed AB (formed in 1944 as a manufacturing company) in 2016 before merging the companies in 2017 to form Magle Chemoswed. In 2019, Adroit Science AB was acquired to increase the development services segment. In 2021, PharmaCept GmbH was acquired as a first step to develop a sales and marketing company in Europe for DSM products.
Two operational areas
Today, the Group includes two operational areas. Magle Chemoswed – a contract development and manufacturing organization (CDMO) with a strong reputation for its high-quality development and manufacturing expertise and PharmaCept – an established sales and marketing company for development and direct sales of DSM products.
